Passive Immunotherapy In Patients With SARS CoV-2

Inclusion Criteria: Patients with SARS-CoV-2 infection, confirmed by any validated microbiological technique, and with one or more symptoms associated with COVID-19 with ≤5 days of evolution and with an oxygen saturation ≥93% breathing room air. In addition, the patients had to present some risk factor for severe disease: * Chronic heart failure (NYHA ≥ 2) * Arterial hypertension under pharmacological treatment * Chronic lung disease: COPD (bronchitis, emphysema or chronic obstruction) with dyspnoea at least on moderate exertion, or moderate-severe asthma (that required inhaled corticosteroids to control symptoms or had received systemic corticosteroids during the last year due to decompensation) * Chronic renal failure (glomerular filtration rate \<60 ml/min/1.73 m², by CKD- ILD) * Diabetes mellitus requiring pharmacological treatment or obesity grade ≥ I (BMI ≥30 Kg/m2). * Patients ≥65 years were included, regardless of other risk factors. Exclusion Criteria: * Duration of symptoms \>5 days * Dyspnoea at rest * Need for supplemental oxygen to maintain O2 saturation \>93% * Solid neoplastic or haematologic disease (except skin cancer) with active treatment in the last 3 months before the onset of symptoms * Patients under chronic corticosteroid treatment (equivalent to prednisone 10 mg/d for at least 28 days) or immunosuppressive treatment * Decompensated liver cirrhosis * Participation in another clinical trial * History of hypersensitivity to haematological derivatives * Pregnancy or lactation, * AST/ALT \>5 times the upper limit of normal or at baseline in patients with chronic liver disease * Any condition that in the opinion of the investigator limits participation in the study. * Patients who had received monoclonal antibodies against SARS-CoV-2